Research On A New Compound TPT-CuCl₂ And Tumor Gene Therapy Mediated By Adenovirus

With development of molecular biology and medicine, scientists made great achievements in cancer therapy. Chemotherapy as a systematic treatment for cancer can make up the deficiency of surgery and radiation and is widely used in cancer therapy. The study identified a novel chemical compound TPT-CuCl₂ which can arrests the cell cycle or induce apoptosis in human cervical carcinomas HeLa cells line. TPT-CuCI2 was found to be effective in tumor growth suppression in rats model. Beside chemotherapy, one of the most promising ways to reach tumor cells is through adenovirus. We have demonstrated a replication-defeicient adenovirus encoding a novel dominant negative D53A mutant of the apoptosis inhibitor Survivin to target tumor cells viability in vitro and in vivo. In xenograft liver cancer model in nude athymus mice, Ad-SW-D53A suppressed liver tumor formation and improved survival advantages in intraperitoneal xenograft mice. These data suggest that adenoviral mediated Survivin pathway may provide a novel approach for cancer gene therapy. Research on prostate cancer has made significant progress in the last few years, gene therapy may prove to be a potent weapon in the fight against locally advanced prostate cancer. We constructed Ad-CMV-Puma in which CMV promoter regulate puma express. We also constructed another tissue specific adenovirus Ad-PSE/PBN-Puma, in which Puma only express in prostate cancer cells and induce rapid apoptosis while without harm to other and normal tissues. Ad-PSE/PBN-Puma would be a promising candidate for prostate cancer gene therapy.